Canada's CCAB likes India for manufacturing its antibody products; Alveda buys IGI Laboratories;

> After partnering with India's Zydus Cadila for its first antibody-based cancer treatments, Canada's Centre for Commercialisation of Antibodies and Biologics (CCAB) says it is impressed by India's manufacturing capabilities and will look for partnerships there for some of its other 1,000 antibodies. Report

> Canada's Alveda Pharmaceuticals, which uses European CMOS to produce its generic injectable drugs, will be acquired by New Jersey based IGI Laboratories, for $47 million. Report

> Mankind Pharma says it has invested Rs 150 crore ($23 million) in its plant at Paonta Sahib and expects to add 35 nutraceutical, food supplement and beverage products by the end of next year. Report

And Finally... Former NBA star Lamar Odom was found unconscious in a Nevada brothel, whose owner said Odom had taken large amounts of an herbal Viagra that the FDA had warned consumers about. Story

Suggested Articles

Gilead expects to sell 1 million to 1.5 million treatment courses of remdesivir in 2020. That means about $3.5 billion in sales, one analsyt figures.

Pfizer and BioNTech followed supply pacts in the U.S. and U.K. with a new deal to deliver 120 million vaccines to Japan in the first half of 2021.

Warp Speed's largest outlay to date, the funding will cover development and manufacturing scale-up of a vaccine that uses proven Sanofi technology.